Talphera earnings date
Want to see TLPH full AI Analyst Report?
Talphera (TLPH) Q3 2026 Earnings Report
TLPH Q3 2026 EPS Results
- Actual EPS
- -$0.05
- Consensus EPS
- -$0.05
- Beat/Miss
- Met expectations
- One Year Ago EPS
- -$0.11
TLPH Q3 2026 Revenue Results
- Actual Revenue
- $0
- Expected Revenue
- $0
- Beat/Miss
- Met expectations
- YoY Revenue Growth
- -100.00%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/12/2026
- Time
- After Close
- Conference Call
- Thursday, November 12, 2026
Talphera's next earnings date is estimated for March 11, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was predominantly optimistic. Management highlighted strong statistical power, a proactive regulatory strategy, an expanded peak-sales estimate above $200 million, supportive external evidence, investigator enthusiasm, and funding expected through a potential 2027 PMA approval. These positives were tempered by an 85% to 90% year-over-year decline in recent enrollment, uncertainty over FDA agreement to early closure, continued difficulty enrolling critically ill patients, and approximately 15% higher cash operating expenses. Overall, the highlights significantly outweighed the lowlights.
Talphera expects to seek FDA agreement to conclude NEPHRO enrollment by December 31, 2026 with the number of available patients enrolled, rather than completing the originally planned target of 70 patients; enrollment is over 75% and the study is over 80% powered for the primary endpoint, FDA feedback is anticipated by the end of this year under a 45-day clock, and topline data are expected within four to six weeks after enrollment is completed. If the FDA says no, the company will continue toward 70 patients, with internal forecasts pushing completion into the first quarter; two conditional financing tranches totaling approximately $16 million are expected to close around topline data and study completion, while $14.2 million of cash at September 30, 2026 is expected to provide sufficient capital through at least a potential Niyad PMA approval expected in 2027. Talphera estimates peak annual U.S. CRRT sales of more than $200 million, expects a 6-month review under the Breakthrough Devices Program, and plans an Investor and Analyst event in the first quarter of 2027.
- NEPHRO Study Enrollment Exceeded 75% with Over 80% Statistical PowerEnrollment in the NEPHRO CRRT registrational study has exceeded 75% of the planned target, and the study is currently over 80% powered for the primary endpoint using the original assumptions. Management stated that the study was originally designed with over 90% power at 70 subjects and expressed confidence that the current enrollment provides enough patients to hit the primary endpoint.
- Proactive FDA Sprint Meeting RequestTalphera submitted a briefing document requesting an FDA Sprint Meeting to seek agreement to conclude enrollment by December 31, 2026 with the number of available patients enrolled at that time, instead of completing the originally planned target of 70 patients. The study remains blinded, and the request is supported by statistical power, safety data, regulatory precedent, and the difficulties of enrolling critically ill ICU patients. The Sprint process has a 45-day clock, with feedback anticipated before the end of 2026.
- Potentially Accelerated Data and PMA TimelineTopline data are expected within four to six weeks after enrollment is completed. If the FDA does not approve early closure, Talphera said it would continue enrolling toward 70 patients, with its internal forecast pushing completion into the first quarter. Management said it plans to file the PMA as quickly as possible and that, under the Breakthrough Devices designation's six-month review, there is a possibility of having Niyad available for use by the end of next year.
- Niyad U.S. CRRT Sales Estimate Raised Above $200 MillionFollowing additional quantitative and qualitative physician research, Talphera increased its estimate of Niyad's peak annual U.S. sales for use during CRRT to more than $200 million. The research evaluated expected anticoagulant utilization, nafamostat's differentiated characteristics, and its potential to address limitations of existing anticoagulation approaches.
- External Evidence Supports CRRT and Nafamostat OpportunityManagement cited a recent New England Journal of Medicine study comparing CRRT with intermittent hemodialysis in critically ill patients with acute kidney injury. The study was stopped early after finding higher mortality among patients receiving intermittent hemodialysis. Talphera said the findings could support further growth of the overall CRRT market. The updated draft KDIGO guidelines also elevated nafamostat as an alternative anticoagulant for CRRT when citrate cannot be used.
- Regulatory Precedent for Smaller CRRT StudiesManagement described precedents in which CRRT studies closed enrollment early and subsequently obtained regulatory approval. A Vantive study originally targeting 160 patients enrolled 34 patients over approximately three years before being renegotiated with the FDA to a 40-subject target. A Fresenius Medical study expected to enroll 50 patients enrolled 31 over approximately 2.5 years and received agreement to submit its 510(k) and NDA; approval of its products was reported around October 19, 2026.
- Nafamostat Safety Database Can Include Ex-U.S. ExperienceTalphera stated that safety data from Japan and other ex-U.S. use will be submitted to the FDA. Management cited more than 40 years of nafamostat use, extensive public-domain literature, and a 2026 publication covering safety information from Japan from 2004 through 2024. The company said there is no fixed number of subjects required for the safety database and that the FDA previously agreed that 70 subjects could be acceptable instead of the earlier 166-subject expectation.
- Study Design and Prior Research Support Secondary EndpointsManagement cited two prior studies with sample sizes of 55 and 60 patients that reported longer filter life, fewer clotting events, and fewer required filters with nafamostat-related approaches. Talphera said its study is differentiated because nafamostat is titrated to a therapeutic window rather than administered solely at a weight-based dose, which management said increases confidence in the secondary endpoints.
- Strong Investigator EngagementManagement reported that investigators remain enthusiastic, with substantial energy and desire to complete the study. Monthly principal-investigator calls continue, and Talphera said it has not observed site fatigue. Investigators were described as motivated by the unmet need and the prospect of having the product available for their patients.
- Cash and Conditional Financing Expected to Fund Through Potential 2027 PMA ApprovalCash totaled $14.2 million as of September 30, 2026. Management said this cash, combined with two remaining conditional financing tranches totaling approximately $16 million, is expected to provide sufficient capital through at least a potential Niyad PMA approval in 2027, assuming the financing conditions are met. The tranches are expected to close around the release of topline data and announcement of study completion.
- Planned Replacement of Form S-3 Shelf RegistrationTalphera plans to file a Form S-3 shelf registration statement to replace its existing Form S-3, which expires on November 30, 2026.
TLPH Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 11, 2027 | 2026 (Q4) | -0.06- | -0.06 | ― | ― |
| Nov 12, 2026 | 2026 (Q3) | -0.05-0.05 | -0.11 | 54.55% (+0.06) | |
| Aug 12, 2026 | 2026 (Q2) | -0.06-0.06 | -0.1 | 40.00% (+0.04) | |
| May 13, 2026 | 2026 (Q1) | -0.07-0.04 | -0.1 | 60.00% (+0.06) | |
| Mar 23, 2026 | 2025 (Q4) | -0.07-0.06 | -0.07 | 14.29% (+0.01) | |
| Nov 12, 2025 | 2025 (Q3) | -0.13-0.11 | -0.13 | 15.38% (+0.02) | |
| Aug 14, 2025 | 2025 (Q2) | -0.13-0.10 | -0.15 | 33.33% (+0.05) | |
| May 14, 2025 | 2025 (Q1) | ―-0.10 | -0.16 | 37.50% (+0.06) | |
| Mar 31, 2025 | 2024 (Q4) | -0.14-0.10 | -0.16 | 37.50% (+0.06) | |
| Nov 13, 2024 | 2024 (Q3) | -0.19-0.13 | -0.08 | -62.50% (-0.05) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

